pharmaphorum

JANUARY 24, 2023

In terms of how the company operates, Auton stated that it currently has more than 13 million genotyped customers, 80% of whom consented for their health data to be used in research. As well as the drug candidate discovered alongside GSK, 23andMe has also developed its own investigational antibody, 23ME-00610.

Genetics 98

Genetics Drugs Genome Project Biobanking 98

The Pharma Data

NOVEMBER 10, 2020

We wanted a tau antibody that would bind to the expressed forms of tau, so we developed a very specific assay,” Dage said. The plasma assay elements include: Capture – a biotin-labeled anti-phosphor-thr217-tau antibody. Detection – a ruthenium-labeled isoform-specific anti-tau antibody. ADNI trial.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Antibody 52

The Pharma Data

SEPTEMBER 2, 2021

Transforming treatment of advanced cancers with antibody drug conjugates (ADCs). Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. Antibody drug conjugates. Antibody drug conjugates. Lead author. Abstract title. Presentation details. Garassino, MC.

Trials 52

Trials Medicine Antibody Clinical Trials 52

The Pharma Data

DECEMBER 9, 2020

Our focus on partnering to accelerate patient access to innovative medicines underscores our commitment to advancing breakthroughs in biomedicine such as antibody drug conjugates, cell therapy, RNAi and more, Ed Zhang, company co-founder, chief operating and business officer, said in a statement. “We million in a second financing round.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

pharmaphorum

JANUARY 29, 2023

Anti-P-selectin antibody Adakveo became the first new treatment for VOCs in SCD patients in decades when it was approved for marketing in the EU, a few months after the FDA gave it the nod in the US, on the strength of the SUSTAIN trial results. That study showed that Adakveo lowered the median annual rate of VOCs to 1.63 compared to 2.98

Genotype 52

Genotype Trials Antibody Regulation 52

The Pharma Data

APRIL 14, 2021

The incidence of Grade 3-4 neutropenia in genotyped patients was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. More information on TROPiCS-04 is available at [link]. About Trodelvy.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52

The Pharma Data

APRIL 7, 2021

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor, a protein frequently expressed in multiple types of epithelial tumors, including metastatic triple-negative breast cancer (TNBC), where high expression is associated with poor survival and relapse.

HR 52

HR Genotype FDA Approval Genotoxicity 52

The Pharma Data

MARCH 25, 2021

SG is an antibody and topoisomerase inhibitor conjugate directed to the Trop-2 cell surface antigen, a protein frequently expressed in multiple types of epithelial tumors, including TNBC, where high expression is associated with poor survival and relapse. More information about ASCENT is available at [link]. About Sacituzumab Govitecan-Hziy.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52